TB-500 dosage and protocols

TB-500 dosage follows a two-phase structure used across virtually all practitioner protocols: a higher-dose loading phase to build systemic levels, followed by a lower-dose maintenance phase to sustain healing activity. Here are the dosing protocols actually used in clinical peptide therapy practice, the reconstitution math, TB-500 half-life pharmacokinetics, cycle length considerations, and how dosing varies by use case — from injury recovery to bodybuilding to veterinary applications.

Why TB-500 dosing uses a loading phase

Unlike peptides with immediate receptor-mediated effects (like growth hormone secretagogues that trigger pulsatile GH release within minutes), TB-500 works through a gradual intracellular process. Actin cytoskeleton remodeling and cell migration promotion require sustained peptide exposure over days to weeks. The loading phase establishes a therapeutic concentration of TB-500 in tissue compartments throughout the body, while the maintenance phase keeps levels above the threshold needed for continued healing activity. This TB-500 dosage protocol structure is borrowed from veterinary equine medicine, where two-phase dosing demonstrated superior outcomes compared to flat dosing in tendon injury treatment.

Standard TB-500 dosing protocols

The moderate loading protocol (5 mg/week) is the most widely recommended starting point. The aggressive protocol (10 mg/week) is typically reserved for acute injuries or post-surgical healing where faster tissue repair is the priority. TB-500 dosage bodybuilding protocols tend toward the higher end — 7.5–10 mg/week loading — though the rationale for exceeding moderate dosing in the absence of acute injury is unclear from the published literature.

TB-500 half-life and pharmacokinetics

The TB-500 half life (sometimes written half-life) is estimated at approximately 5–6 hours based on peptide pharmacokinetic modeling and the Phase 1 trial PK data. This means plasma concentrations of TB-500 fall to half their peak value within about 6 hours of subcutaneous injection. However — and this is critical — TB-500’s biological activity persists far beyond its plasma half-life. Because TB-500 works intracellularly by modifying actin dynamics, once the peptide has entered cells and bound G-actin, the downstream effects (enhanced cell migration, cytoskeletal reorganization) continue for days even after the peptide itself has been cleared from circulation. This is why twice-weekly dosing is sufficient despite the short plasma half-life: the relevant pharmacodynamic effect is cellular, not plasma-concentration-dependent.

Reconstitution math

TB-500 is supplied as lyophilized (freeze-dried) powder in 2 mg or 5 mg vials. Reconstitute with bacteriostatic water (BAC water). The formula: vial amount (mg) ÷ BAC water volume (mL) = concentration (mg/mL). Then: target dose (mg) ÷ concentration (mg/mL) = injection volume (mL).

Units assume a standard U-100 insulin syringe (1 mL = 100 units). For TB-500 5 mg reconstitution, the most practical dilution is 1 mL BAC water, yielding 5 mg/mL — a 2.5 mg dose is then exactly 50 units (half syringe), easy to measure accurately. For TB-500 mixing, always inject the BAC water slowly down the side of the vial and let the powder dissolve by gentle swirling — never shake, as this can denature the peptide.

TB-500 dosage for specific use cases

TB-500 dosage for injury

For acute tendon, ligament, or muscle injuries, the moderate-to-aggressive loading protocol (5–10 mg/week for 4–6 weeks) is standard. TB-500 dosage for injury recovery emphasizes the loading phase, where the goal is rapid accumulation of healing activity at the injury site. Many protocols pair TB-500 with localized BPC-157 injection near the injury for combined systemic + local coverage. After the loading phase, drop to maintenance dosing (2.5–5 mg/week) and continue until functional recovery benchmarks are met, typically 8–12 weeks total.

TB-500 dosage bodybuilding

TB-500 dosage bodybuilding protocols in community practice tend toward 7.5–10 mg/week loading for 4 weeks, then 5 mg/week maintenance for 4–8 weeks. The rationale is supporting connective tissue integrity under heavy training loads and accelerating recovery from training-induced microtrauma. Whether these higher doses provide meaningfully better outcomes than the standard 5 mg/week loading is not established in any published study.

TB-500 dosage for dogs

Veterinary TB-500 dosage for dogs is weight-adjusted: typical protocols use 0.1–0.25 mg/kg body weight, administered subcutaneously twice weekly during a 4-week loading phase and once weekly for maintenance. A 25 kg dog would receive approximately 2.5–6 mg per dose. Veterinary use of TB-500 has a longer safety track record than human use, with equine and canine applications predating human peptide therapy protocols by years.

TB-500 dosing schedule and cycle length

The standard TB-500 dosing schedule (or TB500 dosing schedule) is twice weekly during loading (e.g., Monday and Thursday) and once weekly during maintenance. Total cycle length is 8–12 weeks. If running multiple cycles, a 4-week off period between cycles is commonly recommended, though no published data establishes the optimal inter-cycle interval. The rationale for cycling off is to prevent receptor/pathway desensitization, though given TB-500’s intracellular mechanism (it doesn’t bind a surface receptor), the necessity of cycling is debated. The TB-500 dosage Reddit community generally favors the moderate loading protocol, with most TB 500 dosage Reddit threads recommending 5 mg/week loading as the starting point rather than jumping to aggressive dosing.

TB-500 nasal spray dosage

Some peptide suppliers offer TB-500 in nasal spray formulation. TB-500 nasal spray dosage protocols in community use typically deliver 500 mcg–1 mg per spray, with 2–4 sprays per administration. Intranasal bioavailability for peptides is generally lower than subcutaneous injection, so higher nominal doses may be needed to achieve equivalent systemic exposure. The TB-500 nasal spray route is less studied than injection and should be considered experimental.